You can visit Pharma Live’s Med Ad News website to download podcasts on healthcare issues by John Kamp, the Coalition’s Executive Director.
The 1st is on the defeated but still looming ad tax bill. The 2nd is an overview and analysis of the “New FDA.”
Med Ad News plans to present 3 more podcasts in this series.
A new study by 4 researchers from the Cleveland Clinic showed that industry support of continuing medical education created no bias among participants.
The study acknowledges the controversy surrounding CME funding, then explains how it tested for bias among its participants. It is important to note that no previously published studies have addressed this perceived bias.
From Peter Pitts:
Much brouhaha about the DDMAC letter sent to Dr. Leslie Bauman about her enthusiastic comments about a yet-to-be-approved anti wrinkle injectable.
At first blush, this seems like regulatory creep and cause for First Amendment agita. But it isn’t. This is not a case of the FDA trying to stifle unregulated speech by an individual without “interest.” Dr. Bauman is a clinical investigator for the product she’s been touting. That’s “interest” whether the trial sponsor paid her to do so or not. (In this instance, there was no “pay for play.”) In any case, it’s an unambiguous regulatory no-no.
Read more on their website
Your comments are welcome here.
The February issue of MM&M magazine spotlights Policymed.com blogger Tom Sullivan.
Read the article